Headquarters
Sysmex Group Companies
Select your local website
THANK YOU FOR VISITING OUR POSTER SESSION AT ASCO-GI 2020
RAS status in circulating-tumor DNA (ctDNA) and outcomes during rechallenge treatments with anti-EGFR antibodies in metastatic colorectal cancer (mCRC)
Author
Yu Sunakawa1, Masato Nakamura2, Masahiro Ishizaki3, Masato Kataoka4, Hironaga Satake5, Masaki Kitazono6, Hideyuki Yanagisawa7, Yasuyuki Kawamoto8, Hidekazu Kuramochi9, Hisatsugu Ohori10, Michio Nakamura11, Fumiyo Maeda12, Chihiro Komeno12, Masahiro Takeuchi13, Masashi Fujii14, Takayuki Yoshino15, Wataru Ichikawa16, and Akihito Tsuji17
1：Department of Clinical Oncology, St. Marianna University School of Medicine
2：Aizawa Comprehensive Cancer Center, Aizawa Hospital
3：Department of Surgery, Japan Labour Health and Welfare Organization Okayama Rosai Hospital
4：Department of Surgery, Nagoya Medical Center
5：Cancer Treatment Center, Kansai Medical University Hospital
6：Department of Surgery, Nanpuh Hospital
7：Department of Gastroenterology, Obihiro-Kosei General Hospital
8：Department of Gastroenterology and Hepatology, Hokkaido University Hospital
9：Department of gastroenterological Surgery, Tokyo Women’s Medical University Yachiyo Medical Center
10：Department of Medical Oncology, Ishinomaki Red Cross Hospital
11：Department of Gastroenterology, Sapporo City General Hospital
12 : Sysmex Corporation
13：Department of Clinical Medicine (Biostatistics), Kitasato University School of Pharmacy
14：Department of Digestive Surgery, Nihon University School of Medicine
15：Department of Gastrointestinal Oncology, National Cancer Center Hospital East
16: Division of Medical Oncology, Showa University Fujigaoka Hospital
17：Department of Clinical Oncology, Kagawa University Faculty of Medicine